The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...